The DOI matches its Crossref record; 135 of the 135 references it cites were found in a registry or an index.
Tumor-Suppressor Functions of the TP53 Pathway
Open accessAbstract
The fundamental biological importance of the Tp53 gene family is highlighted by its evolutionary conservation for more than one billion years dating back to the earliest multicellular organisms. The TP53 protein provides essential functions in the cellular response to diverse stresses and safeguards maintenance of genomic integrity, and this is manifest in its critical role in tumor suppression. The importance of Tp53 in tumor prevention is exemplified in human cancer where it is the most frequently detected genetic alteration. This is confirmed in animal models, in which a defective Tp53 gene leads inexorably to cancer development, whereas reinstatement of TP53 function results in regression of established tumors that had been initiated by loss of TP53. Remarkably, despite extensive investigation, the specific mechanisms by which TP53 acts as a tumor suppressor are yet to be fully defined. We review the history and current standing of efforts to understand these mechanisms and how they complement each other in tumor suppression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death
Dixon, S. J., Lemberg, K. M., Lamprecht, M. R., Skouta, R., Zaitsev, E. M., Gleason, C. E., Patel, D. N., Bauer, A. J., Cantley, A. M., Yang, W. S., et al. (2012) · Cell · doi:10.1016/j.cell.2012.03.042 · Cited by 18,691
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · cited 2×
“The importance of the Tp53 gene as a tumor suppressor is highlighted in human cancer where it is the most commonly mutated gene, with mutations found in a broad variety of cancer types (Vogelstein et al. 2000; Petitjean et al. 2007).”
BackgroundThe DNA-damage response in human biology and disease
Jackson, S. P., & Bartek, J. (2009) · Nature · doi:10.1038/nature08467 · Cited by 6,092
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
Regulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744
The BCL-2 protein family: opposing activities that mediate cell death
Youle, R. J., & Strasser, A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2308 · Cited by 4,679
Self-citationMice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Ferroptosis as a p53-mediated activity during tumour suppression
Jiang, L., Kon, N., Li, T., Wang, S.-J., Su, T., Hibshoosh, H., Baer, R., & Gu, W. (2015) · Nature · doi:10.1038/nature14344 · Cited by 3,398
Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate
Ward, P. S., & Thompson, C. B. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.014 · Cited by 3,233
Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
Czabotar, P. E., Lessene, G., Strasser, A., & Adams, J. M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3722 · Cited by 3,219
Self-citationBcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells
Vaux, D. L., Cory, S., & Adams, J. M. (1988) · Nature · doi:10.1038/335440a0 · Cited by 3,219
A microRNA component of the p53 tumour suppressor network
He, L., He, X., Lim, L. P., de Stanchina, E., Xuan, Z., Liang, Y., Xue, W., Zender, L., Magnus, J., Ridzon, D., et al. (2007) · Nature · doi:10.1038/nature05939 · Cited by 2,692
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,551 · cited 2×
“1993) that binds to specific Tp53 response elements in genomic DNA (el-Deiry et al. 1992; Cho et al. 1994) to direct the transcription of a large number of protein-coding genes (Riley et al.”
BackgroundSenescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473
T antigen is bound to a host protein in SY40-transformed cells
LANE, D. P., & CRAWFORD, L. V. (1979) · Nature · doi:10.1038/278261a0 · Cited by 2,394
Vousden, K. H., & Lane, D. P. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2147 · Cited by 2,272
Mice Lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control
Deng, C., Zhang, P., Wade Harper, J., Elledge, S. J., & Leder, P. (1995) · Cell · doi:10.1016/0092-8674(95)90039-x · Cited by 2,113
Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6
Yonish-Rouach, E., Resnftzky, D., Lotem, J., Sachs, L., Kimchi, A., & Oren, M. (1991) · Nature · doi:10.1038/352345a0 · Cited by 2,079
Chromosome 17 Deletions and p53 Gene Mutations in Colorectal Carcinomas
Baker, S. J., Fearon, E. R., Nigro, J. M., Hamilton, S. R., Preisinger, A. C., Jessup, J. M., vanTuinen, P., Ledbetter, D. H., Barker, D. F., Nakamura, Y., et al. (1989) · Science · doi:10.1126/science.2649981 · Cited by 2,066
A Large Intergenic Noncoding RNA Induced by p53 Mediates Global Gene Repression in the p53 Response
Huarte, M., Guttman, M., Feldser, D., Garber, M., Koziol, M. J., Kenzelmann-Broz, D., Khalil, A. M., Zuk, O., Amit, I., Rabani, M., et al. (2010) · Cell · doi:10.1016/j.cell.2010.06.040 · Cited by 2,053
Tumor spectrum analysis in p53-mutant mice
Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., & Weinberg, R. A. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00002-6 · Cited by 2,051
TIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis
Bensaad, K., Tsuruta, A., Selak, M. A., Vidal, M. N. C., Nakano, K., Bartrons, R., Gottlieb, E., & Vousden, K. H. (2006) · Cell · doi:10.1016/j.cell.2006.05.036 · Cited by 2,019
Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions
Gorgoulis, V. G., Vassiliou, L.-V. F., Karakaidos, P., Zacharatos, P., Kotsinas, A., Liloglou, T., Venere, M., DiTullio, R. A., Kastrinakis, N. G., Levy, B., et al. (2005) · Nature · doi:10.1038/nature03485 · Cited by 2,009
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis
Chen, Z., Trotman, L. C., Shaffer, D., Lin, H.-K., Dotan, Z. A., Niki, M., Koutcher, J. A., Scher, H. I., Ludwig, T., Gerald, W., et al. (2005) · Nature · doi:10.1038/nature03918 · Cited by 1,993
The p53 proto-oncogene can act as a suppressor of transformation
Finlay, C. A., Hinds, P. W., & Levine, A. J. (1989) · Cell · doi:10.1016/0092-8674(89)90045-7 · Cited by 1,987
Definition of a consensus binding site for p53
El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., & Vogelstein, B. (1992) · Nature Genetics · doi:10.1038/ng0492-45 · Cited by 1,985
The first 30 years of p53: growing ever more complex.
Levine, A. J., & Oren, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2723 · Cited by 1,967
Transcriptional control of human p53-regulated genes
Riley, T., Sontag, E., Chen, P., & Levine, A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2395 · Cited by 1,921
An Oncogene-Induced DNA Damage Model for Cancer Development
Halazonetis, T. D., Gorgoulis, V. G., & Bartek, J. (2008) · Science · doi:10.1126/science.1140735 · Cited by 1,851
Restoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820 · cited 2×
“Inducible restoration of the wild-type TP53 protein in established tumors that had been elicited by loss of TP53 function leads to tumor regression and prolonged survival of tumor-burdened mice (Martins et al. 2006; Ventura et al. 2007; Xue et al. 2007).”
BackgroundLinzer, D. I. H., & Levine, A. J. (1979) · Cell · doi:10.1016/0092-8674(79)90293-9 · Cited by 1,813
The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice
Adams, J. M., Harris, A. W., Pinkert, C. A., Corcoran, L. M., Alexander, W. S., Cory, S., Palmiter, R. D., & Brinster, R. L. (1985) · Nature · doi:10.1038/318533a0 · Cited by 1,779
p53 Regulates Mitochondrial Respiration
Matoba, S., Kang, J.-G., Patino, W. D., Wragg, A., Boehm, M., Gavrilova, O., Hurley, P. J., Bunz, F., & Hwang, P. M. (2006) · Science · doi:10.1126/science.1126863 · Cited by 1,650
Kruse, J.-P., & Gu, W. (2009) · Cell · doi:10.1016/j.cell.2009.04.050 · Cited by 1,610 · cited 2×
“…system of posttranslational modifications, including phosphorylation, acetylation, and ubiquitination, which impact TP53 protein binding to specific sites in the DNA, protein turnover, and interaction with other proteins that affect TP53 protein transcriptional function (Kruse and Gu 2009).”
BackgroundPetitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598 · cited 1×
“The importance of the Tp53 gene as a tumor suppressor is highlighted in human cancer where it is the most commonly mutated gene, with mutations found in a broad variety of cancer types (Vogelstein et al. 2000; Petitjean et al. 2007).”
BackgroundRegulation of the G2/M transition by p53
Taylor, W. R., & Stark, G. R. (2001) · Oncogene · doi:10.1038/sj.onc.1204252 · Cited by 1,559
Soft-Tissue Sarcomas, Breast Cancer, and Other Neoplasms: A Familial Syndrome?
LI, F. P., & FRAUMENI, J. F. (1969) · Annals of Internal Medicine · doi:10.7326/0003-4819-71-4-747 · Cited by 1,509
Senescence in premalignant tumours
Collado, M., Gil, J., Efeyan, A., Guerra, C., Schuhmacher, A. J., Barradas, M., Benguría, A., Zaballos, A., Flores, J. M., Barbacid, M., et al. (2005) · Nature · doi:10.1038/436642a · Cited by 1,482
Oxidant signals and oxidative stress
Finkel, T. (2003) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(03)00002-4 · Cited by 1,393
Unravelling mechanisms of p53-mediated tumour suppression
Bieging, K. T., Mello, S. S., & Attardi, L. D. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3711 · Cited by 1,387
DRAM, a p53-Induced Modulator of Autophagy, Is Critical for Apoptosis
Crighton, D., Wilkinson, S., O'Prey, J., Syed, N., Smith, P., Harrison, P. R., Gasco, M., Garrone, O., Crook, T., & Ryan, K. M. (2006) · Cell · doi:10.1016/j.cell.2006.05.034 · Cited by 1,380
p53- and Drug-Induced Apoptotic Responses Mediated by BH3-Only Proteins Puma and Noxa
Villunger, A., Michalak, E. M., Coultas, L., Müllauer, F., Böck, G., Ausserlechner, M. J., Adams, J. M., & Strasser, A. (2003) · Science · doi:10.1126/science.1090072 · Cited by 1,327
Self-citationMutant p53 gain of function in two mouse models of Li-Fraumeni syndrome
Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308
Mutant p53: one name, many proteins
Freed-Pastor, W. A., & Prives, C. (2012) · Genes & Development · doi:10.1101/gad.190678.112 · Cited by 1,247
Radiation-induced cell cycle arrest compromised by p21 deficiency
Brugarolas, J., Chandrasekaran, C., Gordon, J. I., Beach, D., Jacks, T., & Hannon, G. J. (1995) · Nature · doi:10.1038/377552a0 · Cited by 1,242 · cited 2×
“The key mediator of TP53induced G1 cell-cycle arrest is thought to be CDKN1a (p21), as shown by cells from Cdkn1a mice that show impaired G1 cellcycle arrest in response to DNA damage and TP53 activation (El-Deiryet al. 1993; Brugarolas et al. 1995; Deng et al. 1995).”
BackgroundThe coordinate regulation of the p53 and mTOR pathways in cells
Feng, Z., Zhang, H., Levine, A. J., & Jin, S. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502857102 · Cited by 1,235
Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li–Fraumeni syndrome
Srivastava, S., Zou, Z., Pirollo, K., Blattner, W., & Chang, E. H. (1990) · Nature · doi:10.1038/348747a0 · Cited by 1,211
Caveolin-1 Null Mice Are Viable but Show Evidence of Hyperproliferative and Vascular Abnormalities
Razani, B., Engelman, J. A., Wang, X. B., Schubert, W., Zhang, X. L., Marks, C. B., Macaluso, F., Russell, R. G., Li, M., Pestell, R. G., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105408200 · Cited by 1,158
p53-Mediated Activation of miRNA34 Candidate Tumor-Suppressor Genes
Bommer, G. T., Gerin, I., Feng, Y., Kaczorowski, A. J., Kuick, R., Love, R. E., Zhai, Y., Giordano, T. J., Qin, Z. S., Moore, B. B., et al. (2007) · Current Biology · doi:10.1016/j.cub.2007.06.068 · Cited by 1,123
The antioxidant function of the p53 tumor suppressor
Sablina, A. A., Budanov, A. V., Ilyinskaya, G. V., Agapova, L. S., Kravchenko, J. E., & Chumakov, P. M. (2005) · Nature Medicine · doi:10.1038/nm1320 · Cited by 1,121
Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome
Lang, G. A., Iwakuma, T., Suh, Y.-A., Liu, G., Rao, V. A., Parant, J. M., Valentin-Vega, Y. A., Terzian, T., Caldwell, L. C., Strong, L. C., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.006 · Cited by 1,069
Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells
Maddocks, O. D. K., Berkers, C. R., Mason, S. M., Zheng, L., Blyth, K., Gottlieb, E., & Vousden, K. H. (2013) · Nature · doi:10.1038/nature11743 · Cited by 1,007
The many roles of FAS receptor signaling in the immune system
Strasser, A., Jost, P. J., & Nagata, S. (2009) · Immunity · doi:10.1016/j.immuni.2009.01.001 · Cited by 968
Self-citationTumor Suppression in the Absence of p53-Mediated Cell-Cycle Arrest, Apoptosis, and Senescence
Li, T., Kon, N., Jiang, L., Tan, M., Ludwig, T., Zhao, Y., Baer, R., & Gu, W. (2012) · Cell · doi:10.1016/j.cell.2012.04.026 · Cited by 912
Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2
Strasser, A., Harris, A. W., Bath, M. L., & Cory, S. (1990) · Nature · doi:10.1038/348331a0 · Cited by 905
Self-citationAwakening guardian angels: drugging the p53 pathway
Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R., & Lane, D. P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2763 · Cited by 881 · cited 2×
“…increasing, or restoring, TP53 function have proven effective in eliciting tumor regression in preclinical models, for example, by using small molecule inhibitors that block the E3 ubiquitin ligase, MDM2 (HDM2), which is the major negative regulator of TP53 (Vassilev 2005; Brown et al. 2009).”
BackgroundPuma is an essential mediator of p53-dependent and -independent apoptotic pathways
Jeffers, J. R., Parganas, E., Lee, Y., Yang, C., Wang, J., Brennan, J., MacLean, K. H., Han, J., Chittenden, T., Ihle, J. N., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00244-7 · Cited by 879
Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function
Hu, W., Zhang, C., Wu, R., Sun, Y., Levine, A., & Feng, Z. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1001006107 · Cited by 862
PML regulates p53 acetylation and premature senescence induced by oncogenic Ras
Pearson, M., Carbone, R., Sebastiani, C., Cioce, M., Fagioli, M., Saito, S., Higashimoto, Y., Appella, E., Minucci, S., Pandolfi, P. P., et al. (2000) · Nature · doi:10.1038/35018127 · Cited by 847
Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis
Eischen, C. M., Weber, J. D., Roussel, M. F., Sherr, C. J., & Cleveland, J. L. (1999) · Genes & Development · doi:10.1101/gad.13.20.2658 · Cited by 819
Non-Cell-Autonomous Tumor Suppression by p53
Lujambio, A., Akkari, L., Simon, J., Grace, D., Tschaharganeh, D. F., Bolden, J. E., Zhao, Z., Thapar, V., Joyce, J. A., Krizhanovsky, V., et al. (2013) · Cell · doi:10.1016/j.cell.2013.03.020 · Cited by 766 · cited 1×
“For example, in a mouse model of hepatocellular carcinoma, TP53 was shown to influence the microenvironment and immune response via a non-tumor-cell-autonomous mechanism, which impacted the rate of tumor expansion and aggressiveness (Lujambio et al. 2013).”
BackgroundRegeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AhpD
Budanov, A. V., Sablina, A. A., Feinstein, E., Koonin, E. V., & Chumakov, P. M. (2004) · Science · doi:10.1126/science.1095569 · Cited by 731
The Tumor Suppressor p53 Down-Regulates Glucose Transporters GLUT1 and GLUT4 Gene Expression
Schwartzenberg-Bar-Yoseph, F., Armoni, M., & Karnieli, E. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-0846 · Cited by 726
DeLeo, A. B., Jay, G., Appella, E., Dubois, G. C., Law, L. W., & Old, L. J. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.5.2420 · Cited by 721
Wild-type p53 can inhibit oncogene-mediated focus formation.
Eliyahu, D., Michalovitz, D., Eliyahu, S., Pinhasi-Kimhi, O., & Oren, M. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.22.8763 · Cited by 692
Kortlever, R. M., Higgins, P. J., & Bernards, R. (2006) · Nature Cell Biology · doi:10.1038/ncb1448 · Cited by 637 · cited 3×
“The TP53 protein controls cellular senescence by activating a number of transcriptional targets that include Cdkn1a, Pml, Pai1, and E2f7 (Pearson et al. 2000; Kortlever et al. 2006; Aksoy et al. 2012), some of which (e.g., Cdkn1a) are notable for additional function in cell-cycle regulation.”
Backgroundp53 regulates glucose metabolism through an IKK-NF-κB pathway and inhibits cell transformation
Kawauchi, K., Araki, K., Tobiume, K., & Tanaka, N. (2008) · Nature Cell Biology · doi:10.1038/ncb1724 · Cited by 637
Modeling the Therapeutic Efficacy of p53 Restoration in Tumors
Martins, C. P., Brown-Swigart, L., & Evan, G. I. (2006) · Cell · doi:10.1016/j.cell.2006.12.007 · Cited by 600 · cited 1×
“Inducible restoration of the wild-type TP53 protein in established tumors that had been elicited by loss of TP53 function leads to tumor regression and prolonged survival of tumor-burdened mice (Martins et al. 2006; Ventura et al. 2007; Xue et al. 2007).”
Backgroundp53: traffic cop at the crossroads of DNA repair and recombination
Sengupta, S., & Harris, C. C. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1546 · Cited by 544
Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice.
Harvey, M., McArthur, M. J., Montgomery, C. A., Butel, J. S., Bradley, A., & Donehower, L. A. (1993) · Nature Genetics · doi:10.1038/ng1193-225 · Cited by 542
Ribeiro, R. C., Sandrini, F., Figueiredo, B., Zambetti, G. P., Michalkiewicz, E., Lafferty, A. R., DeLacerda, L., Rabin, M., Cadwell, C., Sampaio, G., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161479898 · Cited by 541
Distinct p53 Transcriptional Programs Dictate Acute DNA-Damage Responses and Tumor Suppression
Brady, C. A., Jiang, D., Mello, S. S., Johnson, T. M., Jarvis, L. A., Kozak, M. M., Broz, D. K., Basak, S., Park, E. J., McLaughlin, M. E., et al. (2011) · Cell · doi:10.1016/j.cell.2011.03.035 · Cited by 533
Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases
Strasser, A., Cory, S., & Adams, J. M. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.307 · Cited by 532
Self-citationGenomic instability in Gadd45a-deficient mice
Hollander, M. C., Sheikh, M. S., Bulavin, D. V., Lundgren, K., Augeri-Henmueller, L., Shehee, R., Molinaro, T. A., Kim, K. E., Tolosa, E., Ashwell, J. D., et al. (1999) · Nature Genetics · doi:10.1038/13802 · Cited by 510
Hallmarks of senescence in carcinogenesis and cancer therapy
Shay, J. W., & Roninson, I. B. (2004) · Oncogene · doi:10.1038/sj.onc.1207518 · Cited by 502
Maiuri, M. C., Galluzzi, L., Morselli, E., Kepp, O., Malik, S. A., & Kroemer, G. (2010) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.12.001 · Cited by 502
Dankort, D., Filenova, E., Collado, M., Serrano, M., Jones, K., & McMahon, M. (2007) · Genes & Development · doi:10.1101/gad.1516407 · Cited by 481
INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53
Schmitt, C. A., McCurrach, M. E., de Stanchina, E., Wallace-Brodeur, R. R., & Lowe, S. W. (1999) · Genes & Development · doi:10.1101/gad.13.20.2670 · Cited by 458
Metabolic Regulation by p53 Family Members
Berkers, C. R., Maddocks, O. D. K., Cheung, E. C., Mor, I., & Vousden, K. H. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.06.019 · Cited by 446
Kenzelmann Broz, D., Spano Mello, S., Bieging, K. T., Jiang, D., Dusek, R. L., Brady, C. A., Sidow, A., & Attardi, L. D. (2013) · Genes & Development · doi:10.1101/gad.212282.112 · Cited by 443
Rouault, J.-P., Falette, N., Guéhenneux, F., Guillot, C., Rimokh, R., Wang, Q., Berthet, C., Moyret-Lalle, C., Savatier, P., Pain, B., et al. (1996) · Nature Genetics · doi:10.1038/ng1296-482 · Cited by 434
Directing cancer cells to self-destruct with pro-apoptotic receptor agonists
Ashkenazi, A. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2637 · Cited by 432
Aubrey, B. J., Kelly, G. L., Kueh, A. J., Brennan, M. S., O’Connor, L., Milla, L., Wilcox, S., Tai, L., Strasser, A., & Herold, M. J. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.02.002 · Cited by 399
Self-citationThe pathological response to DNA damage does not contribute to p53-mediated tumour suppression
Christophorou, M. A., Ringshausen, I., Finch, A. J., Swigart, L. B., & Evan, G. I. (2006) · Nature · doi:10.1038/nature05077 · Cited by 382
Oncogene-Induced Cell Senescence — Halting on the Road to Cancer
Mooi, W. J., & Peeper, D. S. (2006) · New England Journal of Medicine · doi:10.1056/nejmra062285 · Cited by 371
p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis
Kemp, C. J., Wheldon, T., & Balmain, A. (1994) · Nature Genetics · doi:10.1038/ng0994-66 · Cited by 368
p53-Mediated Hematopoietic Stem and Progenitor Cell Competition
Bondar, T., & Medzhitov, R. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.03.002 · Cited by 342
Integral role of Noxa in p53-mediated apoptotic response
Shibue, T., Takeda, K., Oda, E., Tanaka, H., Murasawa, H., Takaoka, A., Morishita, Y., Akira, S., Taniguchi, T., & Tanaka, N. (2003) · Genes & Development · doi:10.1101/gad.1103603 · Cited by 338
A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer
DiGiammarino, E. L., Lee, A. S., Cadwell, C., Zhang, W., Bothner, B., Ribeiro, R. C., Zambetti, G., & Kriwacki, R. W. (2002) · Nature Structural Biology · doi:10.1038/nsb730 · Cited by 294
The Origins and Evolution of the p53 Family of Genes
Belyi, V. A., Ak, P., Markert, E., Wang, H., Hu, W., Puzio-Kuter, A., & Levine, A. J. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001198 · Cited by 292
Valente, L. J., Gray, D. H. D., Michalak, E. M., Pinon-Hofbauer, J., Egle, A., Scott, C. L., Janic, A., & Strasser, A. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.04.012 · Cited by 291
Self-citationGenetic background alters the spectrum of tumors that develop in p53‐deficient mice
Harvey, M., McArthur, M. J., Montgomery, C. A., Bradley, A., & Donehower, L. A. (1993) · The FASEB Journal · doi:10.1096/fasebj.7.10.8344491 · Cited by 285
The p53 protein is an unusually shaped tetramer that binds directly to DNA.
Friedman, P. N., Chen, X., Bargonetti, J., & Prives, C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3319 · Cited by 264
Kerr, J. B., Hutt, K. J., Michalak, E. M., Cook, M., Vandenberg, C. J., Liew, S. H., Bouillet, P., Mills, A., Scott, C. L., Findlay, J. K., et al. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.08.017 · Cited by 263
Self-citationGalbiati, F., Volonte', D., Liu, J., Capozza, F., Frank, P. G., Zhu, L., Pestell, R. G., & Lisanti, M. P. (2001) · Molecular Biology of the Cell · doi:10.1091/mbc.12.8.2229 · Cited by 259
Selective activation of p53-mediated tumour suppression in high-grade tumours
Junttila, M. R., Karnezis, A. N., Garcia, D., Madriles, F., Kortlever, R. M., Rostker, F., Brown Swigart, L., Pham, D. M., Seo, Y., Evan, G. I., et al. (2010) · Nature · doi:10.1038/nature09526 · Cited by 245
TP53 loss creates therapeutic vulnerability in colorectal cancer
Liu, Y., Zhang, X., Han, C., Wan, G., Huang, X., Ivan, C., Jiang, D., Rodriguez-Aguayo, C., Lopez-Berestein, G., Rao, P. H., et al. (2015) · Nature · doi:10.1038/nature14418 · Cited by 241
Allen, M. A., Andrysik, Z., Dengler, V. L., Mellert, H. S., Guarnieri, A., Freeman, J. A., Sullivan, K. D., Galbraith, M. D., Luo, X., Kraus, W. L., et al. (2014) · eLife · doi:10.7554/elife.02200 · Cited by 238
Cell competition is a tumour suppressor mechanism in the thymus
Martins, V. C., Busch, K., Juraeva, D., Blum, C., Ludwig, C., Rasche, V., Lasitschka, F., Mastitsky, S. E., Brors, B., Hielscher, T., et al. (2014) · Nature · doi:10.1038/nature13317 · Cited by 231
Achatz, M. I. W., Olivier, M., Calvez, F. L., Martel-Planche, G., Lopes, A., Rossi, B. M., Ashton-Prolla, P., Giugliani, R., Palmero, E. I., Vargas, F. R., et al. (2007) · Cancer Letters · doi:10.1016/j.canlet.2005.12.039 · Cited by 217
Michalak, E. M., Villunger, A., Adams, J. M., & Strasser, A. (2008) · Cell Death & Differentiation · doi:10.1038/cdd.2008.16 · Cited by 205
Self-citationIntact p53-Dependent Responses in miR-34–Deficient Mice
Concepcion, C. P., Han, Y.-C., Mu, P., Bonetti, C., Yao, E., D'Andrea, A., Vidigal, J. A., Maughan, W. P., Ogrodowski, P., & Ventura, A. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002797 · Cited by 197
TIGAR Is Required for Efficient Intestinal Regeneration and Tumorigenesis
Cheung, E. C., Athineos, D., Lee, P., Ridgway, R. A., Lambie, W., Nixon, C., Strathdee, D., Blyth, K., Sansom, O. J., & Vousden, K. H. (2013) · Developmental Cell · doi:10.1016/j.devcel.2013.05.001 · Cited by 187
Eischen, C. M., Roussel, M. F., Korsmeyer, S. J., & Cleveland, J. L. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.22.7653-7662.2001 · Cited by 183
Suppression of tumorigenesis by the p53 target PUMA
Hemann, M. T., Zilfou, J. T., Zhao, Z., Burgess, D. J., Hannon, G. J., & Lowe, S. W. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403286101 · Cited by 179
Gao, W., Shen, Z., Shang, L., & Wang, X. (2011) · Cell Death & Differentiation · doi:10.1038/cdd.2011.33 · Cited by 178
p53 Activation by Small Molecules: Application in Oncology
Vassilev, L. T. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm058174k · Cited by 174
Mutations in the p53 and SCID genes cooperate in tumorigenesis.
Nacht, M., Strasser, A., Chan, Y. R., Harris, A. W., Schlissel, M., Bronson, R. T., & Jacks, T. (1996) · Genes & Development · doi:10.1101/gad.10.16.2055 · Cited by 172
Self-citationGermlineTP53Mutations and the Changing Landscape of Li-Fraumeni Syndrome
Kamihara, J., Rana, H. Q., & Garber, J. E. (2014) · Human Mutation · doi:10.1002/humu.22559 · Cited by 165
Role of Promyelocytic Leukemia (Pml) Protein in Tumor Suppression
Rego, E. M., Wang, Z.-G., Peruzzi, D., He, L.-Z., Cordon-Cardo, C., & Pandolfi, P. P. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.4.521 · Cited by 161
Capozza, F., Williams, T. M., Schubert, W., McClain, S. A., Bouzahzah, B., Sotgia, F., & Lisanti, M. P. (2003) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64335-0 · Cited by 157
Puma and to a lesser extent Noxa are suppressors of Myc-induced lymphomagenesis
Michalak, E. M., Jansen, E. S., Happo, L., Cragg, M. S., Tai, L., Smyth, G. K., Strasser, A., Adams, J. M., & Scott, C. L. (2009) · Cell Death & Differentiation · doi:10.1038/cdd.2008.195 · Cited by 147
Self-citationNewton, K., & Strasser, A. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.1.195 · Cited by 146
Self-citationAutophagy, Stress, and Cancer Metabolism: What Doesn't Kill You Makes You StrongerPreprint
Mathew, R., & White, E. (2011) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2012.76.011015 · Cited by 137
The atypical E2F family member E2F7 couples the p53 and RB pathways during cellular senescencePreprint
Aksoy, O., Chicas, A., Zeng, T., Zhao, Z., McCurrach, M. E., Wang, X., & Lowe, S. W. (2012) · Genes & Development · doi:10.1101/gad.196238.112 · Cited by 133
Absence of p53 allows direct immortalization of hematopoietic cells by the myc and raf oncogenes
Metz, T. M., Harris, A. W., & Adams, J. M. (1995) · Cell · doi:10.1016/0092-8674(95)90049-7 · Cited by 123
Increased Oxidative Metabolism in the Li–Fraumeni Syndrome
Wang, P.-Y., Ma, W., Park, J.-Y., Celi, F. S., Arena, R., Choi, J. W., Ali, Q. A., Tripodi, D. J., Zhuang, J., Lago, C. U., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214091 · Cited by 114
Happo, L., Cragg, M. S., Phipson, B., Haga, J. M., Jansen, E. S., Herold, M. J., Dewson, G., Michalak, E. M., Vandenberg, C. J., Smyth, G. K., et al. (2010) · Blood · doi:10.1182/blood-2010-04-280818 · Cited by 112
Self-citationp21 delays tumor onset by preservation of chromosomal stability
Barboza, J., Liu, G., Ju, Z., El‐Naggar, A. K., & Lozano, G. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606343104 · Cited by 110
Integrative genomic analysis reveals widespread enhancer regulation by p53 in response to DNA damage
Younger, S. T., Kenzelmann-Broz, D., Jung, H., Attardi, L. D., & Rinn, J. L. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv284 · Cited by 99
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
THIERS, B. H. (2008) · Yearbook of Dermatology and Dermatologic Surgery · doi:10.1016/s0093-3619(08)70921-3 · Cited by 94
Jiang, D., Brady, C. A., Johnson, T. M., Lee, E. Y., Park, E. J., Scott, M. P., & Attardi, L. D. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1111245108 · Cited by 91
Bax accelerates tumorigenesis in p53-deficient mice.
Knudson, C. M., Johnson, G. M., Lin, Y.-T., & Korsmeyer, S. J. (2001) · PubMed · Cited by 85
Mdm2 and p53 are highly conserved from placozoans to man
Lane, D. P., Cheok, C. F., Brown, C. J., Madhumalar, A., Ghadessy, F. J., & Verma, C. S. (2010) · Cell Cycle · doi:10.4161/cc.9.3.10516 · Cited by 79
The evolution of thymic lymphomas in p53 knockout micePreprint
Dudgeon, C., Chan, C. H., Kang, W., Sun, Y., Emerson, R., Robins, H. S., & Levine, A. J. (2014) · Genes & Development · doi:10.1101/gad.252148.114 · Cited by 78
Specific Requirement for Bax, Not Bak, in Myc-induced Apoptosis and Tumor Suppression in Vivo
Dansen, T. B., Whitfield, J. R., Rostker, F., Swigart, L. B., & Evan, G. I. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m513655200 · Cited by 76
Understanding the non-canonical pathways involved in p53-mediated tumor suppression
Hager, K. M., & Gu, W. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt487 · Cited by 75
Gadd45a Functions as a Promoter or Suppressor of Breast Cancer Dependent on the Oncogenic Stress
Tront, J. S., Huang, Y., Fornace, A. J., Hoffman‐Liebermann, B., & Liebermann, D. A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2177 · Cited by 64
Extracellular Adenosine Sensing—A Metabolic Cell Death Priming Mechanism Downstream of p53
Long, J. S., Crighton, D., O’Prey, J., Mackay, G., Zheng, L., Palmer, T. M., Gottlieb, E., & Ryan, K. M. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.03.016 · Cited by 54
G1 checkpoint failure and increased tumor susceptibility in mice lacking the novel p53 target Ptprv
Doumont, G., Martoriati, A., Beekman, C., Bogaerts, S., Mee, P. J., Bureau, F., Colombo, E., Alcalay, M., Bellefroid, E., Marchesi, F., et al. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600769 · Cited by 40
Cited by
The Global Phosphorylation Landscape of SARS-CoV-2 Infection
Bouhaddou, M., Memon, D., Meyer, B., White, K. M., Rezelj, V. V., Correa Marrero, M., Polacco, B. J., Melnyk, J. E., Ulferts, S., Kaake, R. M., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.034 · Cited by 1,020
Evolving therapeutic landscape of advanced hepatocellular carcinoma
Yang, C., Zhang, H., Zhang, L., Zhu, A. X., Bernards, R., Qin, W., & Wang, C. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00704-9 · Cited by 727
Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome
Kratz, C. P., Achatz, M. I., Brugières, L., Frebourg, T., Garber, J. E., Greer, M.-L. C., Hansford, J. R., Janeway, K. A., Kohlmann, W. K., McGee, R., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0408 · Cited by 534
Understanding the Molecular Genetics of Basal Cell Carcinoma
Pellegrini, C., Maturo, M., Di Nardo, L., Ciciarelli, V., Gutiérrez García-Rodrigo, C., & Fargnoli, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112485 · Cited by 242
Polymorphisms and endometriosis: A systematic review and meta-analyses
Méar, L., Herr, M., Fauconnier, A., Pineau, C., & Vialard, F. (2020) · Human Reproduction Update · doi:10.1093/humupd/dmz034 · Cited by 85
Metadata
- Authors
- Aubrey, B. J., Strasser, A., & Kelly, G. L.
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2016-05
- Volume
- 6
- Issue
- 5
- Pages
- a026062
- ISSN
- 2157-1422 (ISSN-L)
- OpenAlex
- W2346651667
- Cited by
- 327
- References
- 135
- Type
- posted content
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.